Physician profile
Devi Vasu
NPI 1114121829
$2,089.04
in general payments reported to CMS, 2019-2025
17 companies · $349 in 2025
The $349 reported for 2025 was more than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $542 · 2020: $184 · 2021: $142 · 2022: $65.85 · 2023: $164 · 2024: $643 · 2025: $349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,155.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $458.56 | 2024-2025 | Qelbree |
| E.R. Squibb & Sons, L.L.C. | $301.81 | 2024-2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $299.54 | 2019-2021 | |
| Lundbeck LLC | $163.73 | 2019-2025 | Abilify Asimtufii, Rexulti |
| Otsuka America Pharmaceutical, INC. | $159.48 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $149.37 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $124.85 | 2023-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $91.05 | 2019-2024 | Trintellix |
| Neurocrine Biosciences, INC. | $90.63 | 2019-2024 | Ingrezza |
| Alkermes, INC. | $67.27 | 2019-2023 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $45.74 | 2024-2025 | Auvelity |
| Almatica Pharma LLC | $32.82 | 2023 | Gralise |
| Shire North American Group INC | $27.26 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $25.39 | 2019-2023 | Austedo Xr |
| Eisai INC. | $20.06 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $17.00 | 2022 | |
| Allergan, INC. | $14.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devi Vasu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.